Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Will Narrow Topics For Advisory Committees In Response To HRG Suit

Executive Summary

FDA will ask more directed questions of its advisory committees as a way to narrow the amount of information from NDAs that will be provided to the committees, FDA's Office of Training and Communications Director Nancy Smith, PhD, told the Regulatory Affairs Professionals Society Oct. 5.

You may also be interested in...



FDA Aims To Up Transparency By Making Panel Materials Public Sooner

FDA will post advisory committee briefing materials on its Web site at least two business days in advance of meetings, doubling the current lead time in an effort to enhance transparency, according to a 1draft guidance released last week

FDA Aims To Up Transparency By Making Panel Materials Public Sooner

FDA will post advisory committee briefing materials on its Web site at least two business days in advance of meetings, doubling the current lead time in an effort to enhance transparency, according to a 1draft guidance released last week

Public Citizen/FDA Settlement Will Speed Access To Advisory Committee Info

Public access to advisory committee briefing information for non-confidential meetings will be allowed before or on the day of the meeting under a legal settlement between Public Citizen's Health Research Group and FDA. The legal settlement was reached July 6 and takes effect July 16.

Related Content

UsernamePublicRestriction

Register

PS035001

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel